Canadian Sec - Delayed Quote CAD

Bright Minds Biosciences Inc. (DRUG.CN)

Compare
56.00
-1.88
(-3.25%)
At close: January 10 at 3:59:51 PM EST

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.
NameTitlePayExercisedYear Born
Mr. Ian McDonald Co-Founder, CEO, President & Director -- -- 1961
Mr. Ryan E. S. K. Cheung B.Com., CA, CPA Chief Financial Officer 120k -- 1978
Dr. Jan Torleif Pedersen M.Sc., Ph.D. Chief Science Officer & Director 243.55k -- 1965
Dr. Mark A. Smith M.D., Ph.D. Chief Medical Officer 327.54k -- 1955
Mr. Alex Vasilkevich COO & VP of Corporate Development -- -- --
Dr. Emer Leahy M.B.A., Ph.D. Consultant -- -- 1966

Bright Minds Biosciences Inc.

19 Vestry Street
New York, NY 10013
United States
https://brightmindsbio.com
Sector: 
Healthcare
Industry: 
Biotechnology

Description

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Corporate Governance

Bright Minds Biosciences Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

Related Tickers

JBPHF Jacobio Pharmaceuticals Group Co., Ltd.
0.2950
0.00%
 
BMND.NE Biomind Labs Inc.
0.4150
0.00%
 
WBIO.CN WPD Pharmaceuticals Inc.
0.1900
0.00%
 
TYP.AX TRYPTAMINE FPO [TYP]
0.0370
-5.13%
 
DTC.CN Defence Therapeutics Inc.
0.6500
-1.52%
 
ENBI.CN Entheon Biomedical Corp.
0.2750
+7.84%
 
ONCO.CN Onco-Innova
1.2000
0.00%
 
BLAB.CN Britannia Life Sciences Inc.
0.0850
0.00%
 
CYTOF Altamira Therapeutics Ltd.
0.1690
+20.71%
 
MDNA.TO Medicenna Therapeutics Corp.
1.3700
-5.52%